Today: 22 December 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies
11 October 2025
 ·  ·  ·  ·  · 
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche
11 October 2025
 ·  ·  ·  · 
Qualcomm (QCOM) Stock at a Crossroads: Will 5G & AI Ignite a 2025 Breakout or Stall Out?

Qualcomm (QCOM) Stock at a Crossroads: Will 5G & AI Ignite a 2025 Breakout or Stall Out?

Overview: Qualcomm’s Business & Core Technologies Qualcomm is an American multinational semiconductor company founded in 1985 and headquartered in San Diego, CA. It pioneered wireless communication technologies, notably the CDMA cellular standard in the 1990s, and today its inventions underlie
11 October 2025
 ·  ·  ·  ·  · 
1 … 142 143 144 145 146 … 232
Go toTop